Last Updated: 19 April 2026
ImmunityBio is a US biopharmaceutical company with a single approved product: ANKTIVA, an IL-15 receptor superagonist used with BCG to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. The company was formed via the 2021 merger of NantKwest and ImmunityBio and is controlled by billionaire surgeon-inventor Patrick Soon-Shiong, who owns roughly two-thirds of the shares through affiliated entities. Revenue is growing rapidly from a small base, losses remain deep, and the controlled-company governance structure, heavy related-party financing, and FDA warning letter received in March 2026 are material considerations alongside the commercial ramp.
1. Company Snapshot
| Item | Detail |
|---|---|
| Full Name | ImmunityBio, Inc. |
| Ticker | NASDAQ: IBRX |
| Sector / Industry | Biopharmaceutical — Immuno-oncology |
| Founded / Merged | 2014; merged with NantKwest March 2021 |
| Headquarters | Culver City, California, USA |
| Executive Chairman & Global CSO | Patrick Soon-Shiong, MD |
| President & CEO | Richard Adcock |
| Market Cap (11 April 2026) | ~$7.49 billion |
| FY2025 Revenue | $113.3 million (+700% YoY) |
| FY2025 Net Loss | $(351.4) million |
| Employees | ~691 |
| Exchange | Nasdaq Global Select |
| Website | immunitybio.com |
2. Bull Case vs Bear Case
Bull Case
- ANKTIVA revenue grew 700% in FY2025 to $113m and Q1 2026 preliminary revenue was $44.2m — up 168% year-on-year and 15% quarter-on-quarter — showing the commercial launch is still accelerating.
- European Commission conditional marketing authorisation granted 16 February 2026 opens 27 EU member states plus Iceland, Liechtenstein and Norway.
- ANKTIVA has meaningfully better published complete-response rates (45% at 12 months per the FDA label) than established NMIBC CIS competitors Keytruda (19%) and Adstiladrin (23%).
- QUILT-2.005 BCG-naïve pivotal trial fully enrolled in February 2026; sBLA submission targeted Q4 2026 which, if approved, dramatically expands the addressable population.
- Permanent HCPCS J-code (J9028) has been live since January 2025, removing a key reimbursement friction point.
Bear Case
- Revenue of $113m against FY2025 operating cash burn of ~$305m and $380.9m cash at 31 March 2026 leaves a narrow runway; further dilution or debt is likely.
- Share count expanded from ~697m in Q1 2025 to ~1.03bn in Q1 2026, including a $25m Nant Capital convertible-note conversion into 4.6m shares on 31 March 2026 at $5.427.
- FDA issued a warning letter on 13 March 2026 citing misleading promotional claims; the stock fell roughly 21% on 24 March and securities class-action lawsuits were filed, with lead-plaintiff deadline 26 May 2026.
- Patrick Soon-Shiong controls ~66% of shares via Nant Capital, Cambridge Equities, NantWorks and California Capital Equity, creating controlled-company governance and extensive related-party transactions.
- Competitive threat from Johnson & Johnson's TAR-200 (83.5% CR in pivotal data) and CG Oncology's cretostimogene (~46% 12-month CR) could compress ANKTIVA's market share before label expansions arrive.
3. What Does This Company Actually Do?
ImmunityBio sells ANKTIVA (nogapendekin alfa inbakicept-pmln), an IL-15 receptor superagonist delivered intravesically — directly into the bladder — alongside BCG to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumours. It was approved by the FDA on 22 April 2024 and received European Commission conditional marketing authorisation on 16 February 2026.
The mechanism activates natural killer cells, CD8+ cytotoxic T cells and CD4+ helper T cells locally in the bladder, without the systemic toxicity profile of checkpoint inhibitors. In the QUILT-3.032 pivotal study of 77 patients, 62% achieved complete response and 40% maintained complete response for 24 months or longer. Dosing is 400 micrograms intravesically, weekly for six weeks of induction, followed by maintenance at months 4, 7, 10, 13 and 19 — up to 15 total doses over the treatment course.
Essentially 100% of FY2025 revenue came from US ANKTIVA sales. The pipeline is broader but all pre-commercial: N-803 is in combination trials for non-small-cell lung cancer (with pembrolizumab in the Lung-MAP protocol), pancreatic cancer (with aldoxorubicin), and head-and-neck cancer. The company also has a PD-L1-targeting CAR-NK cell therapy in earlier development. The QUILT-2.005 pivotal trial in BCG-naïve NMIBC (366 patients) completed enrolment in February 2026; the sBLA targeting the BCG-naïve indication is planned for Q4 2026. A separate sBLA for ANKTIVA in BCG-unresponsive papillary disease was resubmitted in March 2026.
4. The Business Model
Revenue is pharmaceutical product sales from ANKTIVA, paid under Medicare Part B and commercial reimbursement using the permanent HCPCS J-code J9028 issued in January 2025. Gross margin detail is not broken out in the preliminary Q1 2026 release — the full 10-Q is expected late April or early May 2026. FY2025 operating margin was approximately negative 226% and net margin approximately negative 310% given revenue of $113m against a net loss of $351m.
Manufacturing is largely in-house. The Dunkirk, New York facility (400,000 sq ft, acquired from Athenex in February 2022) handles fill-finish with stated capacity of up to one million vials per year; 170,000 GMP-qualified ANKTIVA doses had been manufactured by early 2026. A California facility (~100,000 sq ft) provides large-scale bioreactor drug-substance capacity.
The supply chain's critical bottleneck is BCG itself — chronically short globally. In May 2024 ImmunityBio signed an exclusive global supply arrangement with Serum Institute of India, which is also co-developing a recombinant BCG (iBCG) programme with ImmunityBio to relieve that shortage.
Subsidy and regulatory-credit dependency: no material government subsidies, grants or tax credits are disclosed as revenue drivers. The company has received FDA Breakthrough Therapy and Orphan Drug designations, which carry regulatory advantages but no direct cash.
5. Financial Health
| Metric | FY2023 | FY2024 | FY2025 | Q1 2026 (prelim) |
|---|---|---|---|---|
| Revenue | ~$0 | $14.7m | $113.3m | $44.2m |
| Net income / (loss) | n/a | $(413.6)m | $(351.4)m | n/a |
| Operating cash flow | n/a | $(391.2)m | $(304.9)m | n/a |
| Cash & marketable securities | n/a | n/a | n/a | $380.9m (31 Mar 2026) |
Revenue trajectory is steep — from essentially zero in FY2023 to $113.3m in FY2025, with Q1 2026 alone at $44.2m implying an annualised run-rate of ~$177m before further growth. Losses are narrowing only slowly relative to revenue: FY2025 net loss of $351m was $62m better than FY2024 but still more than three times revenue. At the FY2025 cash burn of roughly $305m and a cash balance of $380.9m at end-Q1 2026, the implied runway without additional financing is modest — the company has repeatedly used the ATM and related-party financings to bridge.
On 9 April 2026, ImmunityBio announced an additional $75m of non-dilutive funding under its existing Revenue Interest Purchase Agreement with Oberland Capital, bringing total committed capital under that agreement to $375m. On 31 March 2026, Nant Capital converted a $25m convertible promissory note into 4,606,596 common shares at $5.427. Shares outstanding have risen from roughly 697m in Q1 2025 to about 1.03bn in Q1 2026. The company has no dividend.
6. Valuation & Market Data
The following metrics are point-in-time and will move intraday. Sources: Yahoo Finance, Finviz and company filings, dated where noted. Traders should verify current levels before acting.
| Metric | Value | As of |
|---|---|---|
| Market capitalisation | ~$7.49 billion | 11 Apr 2026 |
| Price-to-sales (trailing) | ~66x | Based on FY2025 revenue |
| P/E (trailing) | N/A — loss-making | — |
| EV/EBITDA | N/A — negative EBITDA | — |
| 52-week high | $12.43 | Feb 2026 |
| 52-week low | $1.83 | 2025 |
| Short interest (shares) | ~120.6 million | Jan 2026 |
| Short interest (% float) | ~35–36% | Jan 2026 |
| Days to cover | ~8.3 days | Jan 2026 |
Short interest at roughly 35% of float places IBRX well above biotech peer averages and contributes to the extreme intraday volatility. The 52-week price range of $1.83 to $12.43 — more than sixfold from trough to peak — reflects how binary recent catalysts (EU approval, trial updates, FDA warning letter, class-action filings) have been for the stock.
7. What Are They Building / What's Coming?
ANKTIVA label expansions. The sBLA for BCG-unresponsive papillary disease was resubmitted in March 2026 with long-term data showing 96% disease-specific survival and 83% progression-free survival at 36 months. The QUILT-2.005 pivotal in BCG-naïve NMIBC fully enrolled in February 2026 (366 patients); sBLA submission is targeted for Q4 2026, with reported interim data showing 84% complete response at nine months for ANKTIVA plus BCG versus 52% for BCG alone.
Pipeline. N-803 is being tested in combination with Keytruda in second-line non-small-cell lung cancer via the Lung-MAP protocol, plus earlier-stage programmes in pancreatic and head-and-neck cancer and in a PD-L1 CAR-NK cell therapy.
Manufacturing and supply. Continued ramp of the Dunkirk, NY and California facilities to support the US launch and planned EU rollout. The Serum Institute partnership is central both to BCG supply and to the co-developed recombinant iBCG programme.
Management commentary. The company states it is on track for Q4 2026 sBLA submission for BCG-naïve NMIBC and that the additional Oberland tranche plus Nant debt conversion materially improve the capital stack. Patrick Soon-Shiong publicly defended the company's compliance posture on the Sean Spicer Show in April 2026, stating the TV advertisement cited in the FDA warning letter had never aired.
8. Competitive Landscape
| Therapy | Sponsor | Mechanism | Status | 12-month CR (BCG-unresponsive CIS) |
|---|---|---|---|---|
| ANKTIVA + BCG | ImmunityBio | IL-15 receptor superagonist | FDA (Apr 2024), EMA (Feb 2026) | ~45% |
| Keytruda | Merck | PD-1 checkpoint inhibitor | FDA (Apr 2020) | ~19% |
| Adstiladrin | Ferring | Intravesical IFNα gene therapy | FDA (Dec 2022) | ~23% |
| Cretostimogene | CG Oncology (CGON) | Oncolytic immunovirus | FDA breakthrough, pivotal | ~46% |
| TAR-200 | Johnson & Johnson | Intravesical gemcitabine system | Phase 3 pivotal | ~83.5% (monotherapy reported) |
On reported efficacy in BCG-unresponsive CIS, ANKTIVA ranks ahead of Keytruda and Adstiladrin and broadly comparable to cretostimogene, but well behind J&J's TAR-200 as published. Head-to-head comparisons across trials carry the usual caveats: patient populations, follow-up windows and endpoints differ. Delivery (intravesical immunotherapy) avoids the systemic toxicity profile of checkpoint inhibitors. The 2026–2027 period will see TAR-200 and cretostimogene regulatory decisions that could materially change the competitive landscape before ANKTIVA's BCG-naïve expansion arrives.
9. Leadership and Ownership
Patrick Soon-Shiong, MD — Executive Chairman and Global Chief Scientific & Medical Officer. Surgeon-inventor; developed Abraxane (paclitaxel nanoparticle) via Abraxis BioScience; founder of the NantWorks ecosystem; owner of the Los Angeles Times. Bloomberg estimates his net worth around $16.6 billion as of 2026.
Richard Adcock — President and Chief Executive Officer.
Ownership. Per Schedule 13D filings, Soon-Shiong and affiliated entities control approximately 66.3% of outstanding shares (roughly 745.6m of 1.03bn shares as of 19 February 2026). Vehicles include Nant Capital (~30%), Cambridge Equities (~25%), California Capital Equity (~10%), NantWorks (~10%), and personal trusts. This gives ImmunityBio controlled-company status.
Recent insider transactions (SEC Form 4).
| Name | Date | Type | Shares | Price | Value | Plan |
|---|---|---|---|---|---|---|
| Christobel Selecky (Director) | 16 Jan 2026 | Sell | 50,000 | $5.00 | $250k | 10b5-1 |
| Christobel Selecky (Director) | 20 Jan 2026 | Sell | 25,000 | $7.506 | $188k | 10b5-1 |
| Barry J. Simon (Director) | 20–23 Feb 2026 | Sell | 175,000 | $9.25–$10.25 | ~$1.7m | 10b5-1 (adopted 4 Sep 2024) |
| Nant Capital, LLC | 31 Mar 2026 | Convert to shares | 4,606,596 | $5.427 | $25m (note principal) | Convertible note |
There have been no reported discretionary open-market insider purchases in the last 12 months; recent director sells have been under pre-arranged 10b5-1 plans. The Nant Capital conversion is a related-party transaction that reduces debt but adds dilution.
10. Risks and Challenges
Single-product concentration. ANKTIVA generates essentially all revenue; any commercial, manufacturing or regulatory disruption would be existential in the near term.
Cash burn and dilution. Operating burn materially exceeds revenue; shares outstanding grew roughly 48% year-on-year and further equity or convertible financings are likely.
FDA compliance and litigation. The 13 March 2026 FDA warning letter for misleading promotional claims — and the ensuing class-action lawsuits covering the 19 January to 24 March 2026 period (lead-plaintiff deadline 26 May 2026) — create legal and reputational exposure.
Competitive erosion. TAR-200 and cretostimogene approvals could meaningfully compress ANKTIVA's share of the BCG-unresponsive CIS pool before label expansions arrive.
BCG supply dependency. Global BCG shortage forces reliance on the Serum Institute relationship; the recombinant iBCG programme is still in development.
Related-party and governance risk. 66% insider control, extensive related-party financing (Nant Capital, NantWorks, Oberland), and multiple Soon-Shiong-controlled entities in the NantWorks umbrella create conflicts that minority holders have limited voting ability to address.
Reimbursement risk. J-code J9028 is live, but payer policy revisions, negotiated rates or step-therapy requirements could compress realised pricing.
Clinical read-out risk. The QUILT-2.005 sBLA filing in Q4 2026 and the pending papillary resubmission are both binary.
Stock volatility and short squeeze dynamics. ~35% short interest combined with high retail participation has produced violent intraday moves.
11. Recent Developments
Last 48 hours (17–19 April 2026): No material company-specific announcements detected in this window. The market is digesting the 9 April Q1 2026 preliminary results and the securities class-action filings disclosed earlier in the month.
April 2026. On 6 April the company filed a comprehensive response to the FDA's Office of Prescription Drug Promotion concerning the warning letter, stating the referenced podcast had been removed and the cited television advertisement had never aired. On 9 April, ImmunityBio announced preliminary Q1 2026 net product revenue of $44.2m (+168% YoY, +15% sequential), $380.9m cash, and an additional $75m Oberland Capital non-dilutive tranche bringing committed capital to $375m. Between 12 and 16 April several law firms announced securities fraud class actions covering the 19 January to 24 March 2026 class period, with lead-plaintiff deadline set at 26 May 2026.
March 2026. FY2025 revenue of $113.3m (+700%) and net loss of $(351.4)m were reported on 3 March. On 13 March the FDA issued a warning letter; on 24 March the stock fell roughly 21%. On 26 March the QUILT-2.005 independent data monitoring committee confirmed statistical power and Q4 2026 sBLA timing; on 31 March Nant Capital converted $25m of debt to 4.6m shares at $5.427.
February 2026. European Commission conditional marketing authorisation granted 16 February for ANKTIVA + BCG across EU-27 plus Iceland, Liechtenstein and Norway. Director Barry Simon sold 175,000 shares under a pre-existing 10b5-1 plan between 20 and 23 February.
January 2026. Director Christobel Selecky executed 10b5-1 sales totalling 75,000 shares between 16 and 20 January. Type B FDA meeting held on the papillary indication; the agency requested additional data ahead of sBLA resubmission.
12. Key Dates Coming Up
- Late April / early May 2026: Q1 2026 Form 10-Q filing and earnings call.
- May 2026: ASCO annual meeting and adjacent GU-oncology presentations — expected ANKTIVA data read-outs. See the ChartsView Economic Calendar for the window.
- 26 May 2026: Lead-plaintiff deadline for the securities class actions.
- Q4 2026: Targeted sBLA submission for ANKTIVA + BCG in BCG-naïve NMIBC (QUILT-2.005).
- 2026–2027: FDA decision window on the resubmitted papillary sBLA.
- 2026–2027: Commercial rollout of ANKTIVA across EU territories; continued ramp of Dunkirk, NY and California manufacturing.
You can track IBRX's chart, volume and technicals on ChartsView Live Charts, and discuss the setup with other traders in the ChartsView Forum. For more company research and market coverage, see the ChartsView Blog.
Disclaimer
This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.